Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Peter MacCallum Cancer Centre
Scientific Title
Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor